Brief: Relief Therapeutics - U.S. Collab Partner Identifies Significantly Higher Likelihood Of Surviving & Recovering From Critical Covid-19 In Aviptadil Treated Patients Previously Administered Remdesivir

MindMaze Therapeutics Holding SA

30/11/2021 06:25

Nov 30 (Reuters) - RELIEF THERAPEUTICS HOLDING SA  RLFB.S :
    * SAID ON MONDAY: REPORTS U.S. COLLABORATION PARTNER
IDENTIFIES
SIGNIFICANTLY HIGHER LIKELIHOOD OF SURVIVING & RECOVERING FROM
CRITICAL COVID-19 IN AVIPTADIL TREATED PATIENTS PREVIOUSLY
ADMINISTERED REMDESIVIR
    * REPORTS THAT PARENT COMPANY OF ITS COLLAB PARTNER, NRX
PHARMACEUTICALS, ANNOUNCED IT COMPLETED AN ANALYSIS TO IDENTIFY
CLINICAL EVIDENCE THAT INDICATES SUBSTANTIAL IMPROVEMENT AFTER
TREATMENT WITH AVIPTADIL IN PATIENTS WITH CRITICAL COVID-19 AND
RESPIRATORY FAILURE OVER EXISTING
THERAPIES SUCH AS REMDESIVIR

Source text for Eikon:  ID:nEQ9Pj2Va 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))